shutterstock_1106850689_piotr_swat

Piotr Swat / Shutterstock.com

19 May 2022Sarah Speight

NIH COVID-19 deal broadens access for poorer nations

The Medicines Patent Pool (MPP) and World Health Organization’s (WHO) COVID-19 Technology Access Pool (C-TAP) have signed a deal aiming to open up new technologies to people living in poorer countries.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More on this story

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More on this story

Biotechnology

Kite Pharma enters into licensing agreement with NIH

9 June 2014 Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health that will give it the IP rights to T-cell therapies developed to treat cancer.

NIH chooses not to use ‘march-in rights’ in prostate drug row

21 June 2016 The US National Institutes of Health has decided not to exercise its “march in-rights” for the Xtandi prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility